Optinose US, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.6M
Doctors Paid
14,798
Transactions
106,650
2024 Total
$1.4M
Payment Breakdown by Category
Research$6.1M (38.9%)
Food & Beverage$2.2M (14.4%)
Consulting$1.6M (10.3%)
Travel$819,514 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.1M | 987 | 38.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.2M | 2,599 | 27.2% |
| Food and Beverage | $2.2M | 99,573 | 14.4% |
| Consulting Fee | $1.6M | 774 | 10.3% |
| Travel and Lodging | $819,514 | 2,456 | 5.3% |
| Honoraria | $447,300 | 211 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $117,585 | 38 | 0.8% |
| Education | $32,000 | 8 | 0.2% |
| Grant | $15,000 | 3 | 0.1% |
| Charitable Contribution | $100.00 | 1 | 0.0% |
Payments by Type
General
$9.5M
105,663 transactions
Research
$6.1M
987 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | $3.1M | 0 | 433 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | $994,507 | 2 | 129 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | $795,195 | 0 | 132 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | $463,033 | 0 | 182 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | $237,483 | 0 | 53 |
| Investigator Sponsored Study (IIS) | $103,669 | 0 | 7 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | $96,127 | 1 | 22 |
| A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adults with Bilateral Nasal Polyps using Nasoendoscopic Video OPN-FLU-NP-3104 | $95,419 | 0 | 10 |
| CS-2201 Study | $66,993 | 0 | 8 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps | $15,791 | 0 | 4 |
| A 24-Week Randomized,Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal administration of 186 and 372 microgram of OPN-375 BID in Subjects with CS with or without the presence of Nasal Polyps ONP-FLU-CS-3205 | $14,323 | 0 | 1 |
| A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase OPN-FLU-NP-3103 | $11,250 | 0 | 4 |
| CS2201 | $10,549 | 1 | 1 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps | $3,500 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 592
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Michael Puricelli, M.d, M.D | Otolaryngology | Overland Park, KS | $10.87 | $0 |
| Dr. Joseph Johnson, M.d, M.D | Family Medicine | Winter Springs, FL | $10.87 | $0 |
| Dr. Rana Ali, M.d, M.D | Pulmonary Disease | Ocean, NJ | $10.85 | $0 |
| Dr. Henry Scovern, Md, MD | Allergy & Immunology | Wyomissing, PA | $10.85 | $0 |
| Mark Dykewicz, Md, MD | Allergy & Immunology | Saint Louis, MO | $10.84 | $0 |
| Donald Siao, Md, MD | Family Medicine | San Jose, CA | $10.84 | $0 |
| Dr. Shashwati Kale, M.d, M.D | Family Medicine | San Jose, CA | $10.83 | $0 |
| Dr. Thomas Voitier, M.d, M.D | Internal Medicine | Lafayette, LA | $10.82 | $0 |
| Saffana Hassan, M.d, M.D | Allergy & Immunology | Houston, TX | $10.80 | $0 |
| German Ramos, M.d, M.D | Family Medicine | Houston, TX | $10.79 | $0 |
| James Ransom, M.d, M.D | Allergy & Immunology | Topeka, KS | $10.78 | $0 |
| Karen Boone, M.d, M.D | Otolaryngology | Saint Peters, MO | $10.78 | $0 |
| Dr. Edward Somma, M.d, M.D | Internal Medicine | Hillside, NJ | $10.72 | $0 |
| Alvin Raymond Tan, M.d, M.D | Nephrology | Katy, TX | $10.65 | $0 |
| Dr. Juan Botto, M.d, M.D | Internal Medicine | Houston, TX | $10.65 | $0 |
| Dr. Clinton Young, M.d, M.D | Internal Medicine | Greensboro, NC | $10.65 | $0 |
| Dr. Craig Herther, M.d, M.D | Otolaryngology | Dubuque, IA | $10.65 | $0 |
| Dr. Michael Wert, M.d, M.D | Internal Medicine | Greensboro, NC | $10.65 | $0 |
| Jennings Nestor, Md, MD | Internal Medicine | Charleston, SC | $10.65 | $0 |
| Thang Tran, Md, MD | Internal Medicine | San Jose, CA | $10.63 | $0 |
| Richard Wasserman, Md, Phd, MD, PHD | Allergy & Immunology | Dallas, TX | $10.62 | $0 |
| Mark Grosinger, Do, DO | Otolaryngology/Facial Plastic Surgery | Cincinnati, OH | $10.52 | $0 |
About Optinose US, Inc.
Optinose US, Inc. has made $15.6M in payments to 14,798 healthcare providers, recorded across 106,650 transactions in the CMS Open Payments database. In 2024, the company paid $1.4M. The top product by payment volume is Xhance ($9.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Otolaryngology ($3.9M to 3,210 doctors).
Payment categories include: Food & Beverage ($2.2M), Consulting ($1.6M), Research ($6.1M), Travel & Lodging ($819,514).
Optinose US, Inc. is associated with 2 products in the CMS Open Payments database.